riluzole has been researched along with B16 Melanoma in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biechele, TL | 1 |
| Camp, ND | 1 |
| Fass, DM | 1 |
| Kulikauskas, RM | 1 |
| Robin, NC | 1 |
| White, BD | 1 |
| Taraska, CM | 1 |
| Moore, EC | 1 |
| Muster, J | 1 |
| Karmacharya, R | 1 |
| Haggarty, SJ | 1 |
| Chien, AJ | 1 |
| Moon, RT | 1 |
1 other study available for riluzole and B16 Melanoma
| Article | Year |
|---|---|
Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Gene Expression Regulation; Genes, | 2010 |